Table 4.
Analytes | Experiment Type | Detection method | Sampling technique (if applicable) | LOD | Reference |
---|---|---|---|---|---|
DA, 5HT | Method development | Microelectrode | DA: 90 nM 5HT: 60 nM |
[101] | |
DA, 5HT | Method development | Microelectrode | DA: 1 μM* 5HT: 100 nM* |
[111] | |
DA, 5HT | Method development | Surface-modified microelectrode | DA: 0.3–0.9μM 5HT: 1.7 μM |
[102, 104] | |
DA, 5HT | Method development | Surface-modified microelectrode | DA: 8 nM 5HT: 500μM* |
[103] | |
DA, 5HT | Method development w/testing on ex vivo samples | Microelectrode | DA: 8 nM 5HT: 0.25μM* |
[112] | |
DA, EP | Method development | Surface-modified microelectrode | DA: 67 μM EP: 69 μM |
[105] | |
DA, EP | Method development | Surface-modified microelectrode | DA: 0.2–0.5μM EP: 0.8 –3.5μM |
[106, 108] | |
DA, EP | Method development | Microelectrode | Not reported | [107] | |
DA, EP, NE | Method development | Microelectrode | 1 μM* | [113] | |
DA, EP, NE | Method development | Enzyme-modified biosensor | DA: 0.2 μM EP: 0.3 μM NE: 0.4 μM |
[109] | |
DA, EP, NE, 5HT | Method development w/in vivo testing | Microelectrode | DA: 10 nM EP: 1 μM* NE: 1 μM* 5HT: 0.5 μM* |
[110] | |
L-NE, D- NE, L-EP, D-EP | Method development | CE-UV | NE: 0.12 mM* EP: 0.11 mM* |
[117] | |
DA, 5HT, NE | Method development w/in vivo and ex vivo testing and pharmacological manipulation | LC-FLD | Microdialysis | 0.2–0.3 nM | [118] |
DA, 5HT | Method development w/in vivo testing & pharmacological manipulation | LC-EC | Microdialysis | DA: 0.5 nM 5HT: 0.25 nM |
[75] |
DA, NE | Method development w/in vivo testing & pharmacological manipulation | LC-EC | Microdialysis | DA: 0.25–1 nM NE: 0.2–0.25 nM 5HT: 0.4–2.5 nM |
[76, 124] |
DA, NE, 5HT | Method development w/in vivo testing & pharmacological manipulation | LC-ED | Microdialysis | DA: 0.1–0.25 nM NE: 0.2–0.25 nM 5HT: 0.3–0.5 nM |
[121–123] |
DA, 5HT | Method development w/in vivo testing & pharmacological manipulation | LC-PFET | Microdialysis | DA: 180 pM 5HT: 150 pM |
[116] |
DA, NE, 5HT | Method development w/in vivo testing & pharmacological manipulation | LC/MS/MS | Microdialysis | DA: 10 nM NE: 10 nM 5HT: 5 nM |
[119] |
DA, NE, EP | Method development w/testing in vivo and ex vivo samples | LC/MS/MS | Microdialysis | DA: 0.25 nM NE: 5 nM EP: 5 nM |
[120] |
DA, 5HT, EP | Method development | CE-EC on microfluidic chip | Microdialysis | DA: 1.6 μM 5HT: 2.0 μM EP: 2.5 μM |
[115] |
DA, EP, NE | Method development | CE-EC | DA: 0.9 μM EP: 1.0 μM NE: 0.8 μM |
[114] | |
DA, 5HT | Method development for ex vivo sample prep and analysis | CE-EC | 100 μM* | [126] | |
DA, NE, EP | Method development & ex vivo sample testing | CE-EC on microfluidic chip | DA: 1.7 μM EP: 0.45 μM |
[125] | |
DA | Method development | Hybrid-mode electrode array | ≥ 100 nM* | [145] | |
DA | Method development | Surface modified electrode | 5–80 nM | [127, 130, 131, 133, 138–141] | |
DA | Method development | Surface modified electrode | 0.2–3.4 μM | [128, 129, 132, 134–136, 142, 144, 146, 147, 149, 168] | |
DA | Method development | Surface modified electrode | 25–51 μM | [137, 150] | |
DA | Method development | Surface modified electrode | 80 μM* | [143] | |
DA | Method development | Microelectrode | 10 μM* | [148, 169] | |
DA | Method development | Microelectrode w/analogue background subtraction | Not reported | [151] | |
DA | Method development w/in vivo testing & pharmacological manipulation | CE-LIF | Microdialysis | 2 nM | [74] |
DA | Method development | Microfluidic chip based electrochemical cell | 2 μM | [152] | |
DA | Method development | CE-EC on microfluidic chip | 60–650 nM | [153, 154, 157] | |
DA | Method development w/testing on cell cultures | CE-EC on microfluidic chip | Microdialysis | 9 μM | [155] |
DA | Method development | FIA-EC on microfluidic chip | 74 nM | [156] | |
DA | Method development | Reactor column- EC | 100 nM | [158] | |
DA | Method development w/testing in cell culture | Surface modified electrode | Microdialysis | ≤ 25 nM | [159] |
DA | Method development | FIA-EC | 0.2 μM | [162] | |
DA | Method development w/in vivo testing & pharmacological manipulation | LC-EC | Microdialysis | 2.5–5 nM | [160, 161] |
DA | Method development w/testing in cell culture | chemiluminescent imaging | 10 nM | [163] | |
DA | Method development w/testing in cell culture | CE-EC on microfluidic chip | 59 nM | [164] | |
NE | Method development | Surface modified electrode | 5 nM | [165] | |
5HT | Method development w/in vivo testing & pharmacological manipulation | CE-LIF | Microdialysis | 0.25 nM | [166] |
5HT | Method development w/in vivo testing & pharmacological manipulation | LC-EC | Microdialysis | 56 pM | [167] |
indicates lowest detected concentration.